Stocktoria
Takeda Pharmaceutical Company Limited 4502.T
Takeda Pharmaceutical Company Limited (4502.T) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 3.83% (safety: safe). FY2026 revenue was $4.51T at a -3.4% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 23 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.017 |
| Retained earnings / assets | 0.046 |
| EBIT / assets | 0.03 |
| Equity / liabilities | 0.919 |
FAQ
Is 4502.T financially healthy?
Takeda Pharmaceutical Company Limited's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does 4502.T pay a dividend, and is it safe?
Yes. Takeda Pharmaceutical Company Limited pays a dividend yielding about 3.83% with a -204.7% payout ratio, rated “safe” for safety.
How profitable is 4502.T?
In FY2026, Takeda Pharmaceutical Company Limited had a net margin of -3.4% and a return on equity of -2.1%.
Source: company filings via Yahoo Finance · JP · as of 2026-03-31. Figures in JPY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.